Investor Information
Below are some facts about current conditions and trends that lead us to believe in a huge potential market for our products.

Clinical Demand

• 16 million people with diabetes in the United States
• 798,000 new cases annually and a prevalence of approximately 6% of the population
• Of this group -15% of patients with diabetes will develop a lower extremity ulcer during the course of their disease
• 14-20% of these patients will require limb amputation
• Foot ulceration is the precursor to approximately 85% of lower extremity amputations
  Autologous, bioengineered grafts can provide an adjunct therapy to this clinical problems

Market Demand

• The demand for alternative (Non- animal) testing methods is a growing global concern
• Mortality rates for burn victims is 35% on average
• 86,000 amputations were performed in 1996 in the United States due to diabetic leg ulcers and non-healing wounds
• Ocular surface disorders due to chemical burns, Stevens-Johnson syndrome and Limbal Stem Cell Deficiency leads to irreversible vision loss for thousands of people

An Economic Problem

• Costs for ulcer care in the United States have been estimated in the range of $4,595 per ulcer episode to nearly $28,000 for the 2 years after diagnosis
• Reports indicate $5,457 per year per ulcer patient or total national annual costs of $5 billion
• Total costs for diabetic foot ulcer treatment in the United States, which include ulcer care and amputations, can approach $6 billion annually

To find out more, contact:

Habib Torfi, President
Invitrx, Inc.
23322 Madero, Ste. J
Mission Viejo, CA 92691-2731

(949) 636-9863
htorfi@invitrx.com